Cyproterone acetate EP Impurity A
CAS: 2701-50-0
Ref. 3D-IC180619
25mg | A consultar | ||
50mg | A consultar | ||
100mg | A consultar | ||
250mg | A consultar |
Información del producto
- (1β,2β)-17-(Acetyloxy)-1,2-dihydro-3′H-cyclopropa[1,2]pregna-1,4,6-triene-3,20-dione
- 17α-Hydroxy-1α,2α-Methylenepregna-4,6-Diene-3,20-Dione-17-Acetate
- 1α,2α-Methylene-3,20-dioxo-pregna-4,6-dien-17α-acetoxy
- 3′H-Cyclopropa[1,2]pregna-1,4,6-triene-3,20-dione, 17-(acetyloxy)-1,2-dihydro-, (1β,2β)-
- 3′H-Cyclopropa[1,2]pregna-1,4,6-triene-3,20-dione, 1β,2β-dihydro-17-hydroxy-, acetate
- Cyclopropa[1,2]cyclopenta[a]phenanthrene, 3′H-cyclopropa[1,2]pregna-1,4,6-triene-3,20-dione deriv.
- Pregna-4,6-diene-3,20-dione, 17-hydroxy-1α,2α-methylene-, acetate
Cyproterone acetate EP Impurity A is a metabolite of cyproterone acetate. Cyproterone acetate is an androgen receptor antagonist drug product which is used in the treatment of prostate cancer and male pattern hair loss. Cyproterone acetate EP Impurity A has been found to be toxic to rats when administered orally, with LD50 values of 40-120 mg/kg, depending on the study. It also has been shown to inhibit hepatic p450 enzymes in rats after oral administration.
Cyproterone acetate EP Impurity A is an impurity standard for cyproterone acetate and is available as a pure compound or as a custom synthesis. This impurity can be analyzed using HPLC with UV detection at 210 nm or by GC with flame ionization detection at 230°C. The purity of this compound can be confirmed using NMR spectroscopy, melting point determination, or elemental analysis.END>
NAME
Propiedades químicas
Consulta técnica sobre: 3D-IC180619 Cyproterone acetate EP Impurity A
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.